{
    "id": 15897,
    "fullName": "MAPK1 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MAPK1 amp indicates an increased number of copies of the MAPK1 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5594,
        "geneSymbol": "MAPK1",
        "terms": [
            "MAPK1",
            "ERK",
            "ERK-2",
            "ERK2",
            "ERT1",
            "MAPK2",
            "p38",
            "p40",
            "p41",
            "p41mapk",
            "p42-MAPK",
            "P42MAPK",
            "PRKM1",
            "PRKM2"
        ]
    },
    "variant": "amp",
    "createDate": "12/30/2015",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14295,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) prevented growth of transformed cells with Mapk1 amplification (PMID: 29760222).",
            "molecularProfile": {
                "id": 16167,
                "profileName": "MAPK1 amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11575,
                    "pubMedId": 29760222,
                    "title": "ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29760222"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14294,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib; GDC-0973) prevented growth of transformed cells with Mapk1 amplification (PMID: 29760222).",
            "molecularProfile": {
                "id": 16167,
                "profileName": "MAPK1 amp"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11575,
                    "pubMedId": 29760222,
                    "title": "ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29760222"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAPK1 amplification conferred resistance to WZ4002 in non-small cell lung cancer cells harboring an EGFR E746_A750del/T790M double mutation in culture (PMID: 22961667).",
            "molecularProfile": {
                "id": 16168,
                "profileName": "EGFR E746_A750del EGFR T790M MAPK1 amp"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4187,
                    "pubMedId": 22961667,
                    "title": "Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22961667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3815,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of the MEK inhibitor CI-1040 overcame resistance to WZ4002 in non-small cell lung cancer cells harboring an EGFR E746_A750del/T790M double mutation and MAPK1 amplification, resulting in inhibition of cell growth in culture (PMID: 22961667).",
            "molecularProfile": {
                "id": 16168,
                "profileName": "EGFR E746_A750del EGFR T790M MAPK1 amp"
            },
            "therapy": {
                "id": 3350,
                "therapyName": "CI-1040 + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4187,
                    "pubMedId": 22961667,
                    "title": "Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22961667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3816,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) overcame resistance to WZ4002 in non-small cell lung cancer cells harboring an EGFR E746_A750del/T790M double mutation and MAPK1 amplification, resulting in inhibition of cell growth in culture (PMID: 22961667).",
            "molecularProfile": {
                "id": 16168,
                "profileName": "EGFR E746_A750del EGFR T790M MAPK1 amp"
            },
            "therapy": {
                "id": 3351,
                "therapyName": "Trametinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4187,
                    "pubMedId": 22961667,
                    "title": "Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22961667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4488,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion, and amplification of NRAS, MAPK1, and CRKL in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18237,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4489,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplification of NRAS, MAPK1, and CRKL were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18237,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4496,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion and amplification of CRKL and MAPK1 were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18262,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16167,
            "profileName": "MAPK1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16168,
            "profileName": "EGFR E746_A750del EGFR T790M MAPK1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18237,
            "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18262,
            "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}